Pemphigus Vulgaris
Pemphigus vulgaris (PV) is a rare but serious autoimmune disease marked by fragile, superficial blisters and raw erosions of the skin and mucous membranes. It develops when the immune system makes autoantibodies against the proteins that hold skin cells together (desmoglein 1 and 3). This causes the cells to separate (acantholysis) and damages the epidermis. If it is not diagnosed and treated promptly, the disease can lead to sepsis and fluid loss and can be life-threatening.
At Haute-Derma, we understand the pain and emotional strain that pemphigus brings. Our goal goes beyond controlling the visible lesions: we also work to restore the skin barrier, minimize medication side effects and improve your overall quality of life.
Our Approach to Treating Pemphigus Vulgaris
Because pemphigus vulgaris is a chronic autoimmune disease with a complex course, Haute-Derma uses a specialized, multidisciplinary and highly individualized care model:
- Accurate diagnosis and staging: We grade disease activity (mild, moderate, severe) using internationally recognized clinical scores such as the PDAI (Pemphigus Disease Area Index) to build a targeted treatment plan.
- Personalized immunosuppressive therapy: Doses are tailored to each patient to bring about remission as quickly as possible, with a proactive plan to monitor and prevent side effects affecting the liver, kidneys, bones and immune system.
- Specialized skin and mucosal wound care: Sterile techniques and advanced biological dressings reduce pain, speed re-epithelialization, prevent mucosal adhesions and guard against secondary infection.
How We Diagnose Pemphigus Vulgaris at Haute-Derma
To confirm the diagnosis and avoid confusion with other autoimmune blistering diseases, Haute-Derma follows a gold-standard diagnostic workup:
- Clinical examination and history: We assess the blisters (flaccid, easily broken, on normal or reddened skin), test for the Nikolsky sign (positive) and carefully examine the mucous membranes (mouth, throat, eyes, genitals).
- Skin biopsy for histology: A sample from the edge of a blister is stained with H&E to show the characteristic suprabasal acantholysis (the "row of tombstones" appearance) forming a blister within the epidermis.
- Direct immunofluorescence (DIF): The single most important test, performed on normal-looking skin next to a blister, to detect IgG and/or C3 deposited in a net-like pattern around the keratinocytes (the "fishnet" pattern).
- Indirect immunofluorescence (IIF) and ELISA: Blood tests that measure autoantibodies against desmoglein 1 (Dsg1) and desmoglein 3 (Dsg3), helping to distinguish pemphigus from other conditions, track response to treatment and anticipate relapse.
How Pemphigus Vulgaris Is Treated at Haute-Derma
Our treatment plans follow current international guidelines and combine systemic therapy with local care:
- Systemic corticosteroids: The cornerstone of the initial phase, used to bring lesions under control quickly. Our specialists calculate the dose carefully and follow a strict tapering schedule to prevent the disease from flaring again.
- Additional immunosuppressants: Non-steroid drugs (such as azathioprine, mycophenolate mofetil or cyclophosphamide) boost the effectiveness of treatment and act as "steroid-sparing" agents to keep long-term complications to a minimum.
- Advanced biologic therapy (rituximab): For moderate to severe or treatment-resistant disease, the anti-CD20 monoclonal antibody rituximab targets the B lymphocytes that produce the faulty antibodies, achieving high rates of complete remission and longer periods of stability.
- Local and mucosal care: Medicated pain-relieving mouthwashes and protective oral gels before meals; mild antiseptics and non-adherent dressings on skin lesions so the skin is not stripped away at dressing changes.
